title: Vinorelbine plus low-dose cisplatinum with concomitant radiotherapy for the treatment of locally advanced or inoperable non-metastasized non-small-cell lung cancer (stage I-IIIB): a phase II study.
abstract: In a phase II study, we assessed the toxicity and efficacy of daily low-dose cisplatin (6 mg/m2) and weekly vinorelbine (15 mg/m2) with concurrent thoracic irradiation (60 Gy) for locally advanced non-metastasized non-small-cell lung cancer. The overall response rate was 65%, complete response 12% and the median overall survival was 64 weeks.
authors.affiliation: Department of Oncology, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland.
authors.forename: Ralph
authors.initials: R
authors.lastname: Winterhalder
authors.forename: Simone
authors.initials: S
authors.lastname: Deschler-Marini
authors.forename: Christine
authors.initials: C
authors.lastname: Landmann
authors.forename: Roger
authors.initials: R
authors.lastname: Kann
authors.forename: Jakob
authors.initials: J
authors.lastname: Passweg
authors.forename: Richard
authors.initials: R
authors.lastname: Herrmann
authors.forename: Miklos
authors.initials: M
authors.lastname: Pless
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine
chemical_list: D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine